Real-World Use of BTK Inhibitors in Chronic Lymphocytic Leukemia

home / news-network / real-world-use-of-btk-inhibitors-in-chronic-lymphocytic-leukemia

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss the real-world use of BTK inhibitors for patients with chronic lymphocytic leukemia.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, on factors for selecting a BTK inhibitor or a venetoclax-based regimen in chronic lymphocytic leukemia.

EP. 1: Factors for Selecting a BTK Inhibitor vs Other Regimens in CLL

By Mazyar Shadman, MD, MPH
Marc S. Hoffmann, MD

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, on factors for selecting a BTK inhibitor or a venetoclax-based regimen in chronic lymphocytic leukemia.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss how to use data for BTK inhibitors to inform clinical decisions in chronic lymphocytic leukemia.

EP. 2: Translating BTK Inhibitor Data into Clinical Decision-Making

By Mazyar Shadman, MD, MPH
Marc S. Hoffmann, MD

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss how to use data for BTK inhibitors to inform clinical decisions in chronic lymphocytic leukemia.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss findings from the SEQUOIA trial of zanubrutinib in treatment-naive chronic lymphocytic leukemia.

EP. 3: The SEQUOIA Trial of Zanubrutinib vs BR in Previously Untreated CLL/SLL

By Mazyar Shadman, MD, MPH
Marc S. Hoffmann, MD

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss findings from the SEQUOIA trial of zanubrutinib in treatment-naive chronic lymphocytic leukemia.